Search Within

Lee M Krug

  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (15)
  2. Meeting Abstract (5)
Groups
  1. Biostatistics Service (20)
  2. Epidemiology and Biostatistics (20)
  3. Department of Medicine (15)
  4. Solid Tumor Oncology Division (15)
  5. Thoracic Oncology (15)
  6. Surgery (12)

More Groups

People
  1. Mark Kris (11)
  2. Valerie Rusch (10)
  3. Venkatraman Seshan (9)
  4. Vincent Miller (8)
  5. Christopher Azzoli (7)
  6. Robert Heelan (6)

More People

Years
  1. 2017 (2)
  2. 2016 (2)
  3. 2014 (2)
  4. 2012 (1)
  5. 2011 (2)
  6. 2010 (1)

More Years

Publications
  1. Journal of Thoracic Oncology (6)
  2. Clinical Cancer Research (4)
  3. Journal of Clinical Oncology (4)
  4. Cancer (2)
  5. International Journal of Radiation Oncology, Biology, Physics (2)
  6. Cancer Immunology, Immunotherapy (1)

More Publications

Publishers
  1. Elsevier Inc. (8)
  2. American Association for Cancer Research (4)
  3. American Society of Clinical Oncology (4)
  4. Wiley Blackwell (2)
  5. Elsevier Ireland Ltd. (1)
  6. Springer (1)

Results (20)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma
    Journal Article

    Zauderer, M. G.; Tsao, A. S.; Dao, T.; Panageas, K.; Lai, W. V.; Rimner, A.; Rusch, V. W.; Adusumilli, P. S.; Ginsberg, M. S.; Gomez, D.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Improved outcomes with modern lung-sparing trimodality therapy in patients with malignant pleural mesothelioma
    Journal Article

    Shaikh, F.; Zauderer, M. G.; von Reibnitz, D.; Wu, A. J.; Yorke, E. D.; Foster, A.; Shi, W.; Zhang, Z.; Adusumilli, P. S.; Rosenzweig, K. E.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Randomized phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodality therapy
    Meeting Abstract

    Zauderer, M. G.; Dao, T.; Rusch, V. W.; Ginsberg, M. S.; Tsao, A. S.; Panageas, K.; Stergiou, A. M.; Scheinberg, D. A.; Krug, L. M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma
    Journal Article

    Rimner, A.; Zauderer, M. G.; Gomez, D. R.; Adusumilli, P. S.; Parhar, P. K.; Wu, A. J.; Woo, K. M.; Shen, R.; Ginsberg, M. S.; Yorke, E. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Should all limited-stage small cell lung cancer be treated alike?: Impact of AJCC stage on brain metastasis, survival, and patterns of failure
    Meeting Abstract

    Wu, A. J.; Gillis, A.; Foster, A.; Woo, K.; Zhang, Z.; Gelblum, D. Y.; Downey, R. J.; Rosenzweig, K. E.; Ong, L.; Perez, C. A.; more...
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Should all limited-stage small cell lung cancer be treated alike? Impact of AJCC stage on brain metastasis, survival, and patterns of failure
    Meeting Abstract

    Wu, A. J.; Gillis, A.; Foster, A.; Woo, K.; Zhang, Z.; Gelblum, D. Y.; Downey, R. J.; Rosenzweig, K. E.; Ong, L.; Perez, C. A.; more...
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci
    Journal Article

    Krug, L. M.; Ragupathi, G.; Hood, C.; George, C.; Hong, F.; Shen, R.; Abrey, L.; Jennings, H. J.; Kris, M. G.; Livingston, P. O.
    Cancer Immunology, Immunotherapy (2012)

    Fulltext@MSK | Save
  • Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as adjuvant therapy in patients with malignant pleural mesothelioma (MPM)
    Meeting Abstract

    Krug, L. M.; Tsao, A. S.; Kass, S.; Rusch, V. W.; Travis, W. D.; Panageas, K.; Adusumili, P. S.; Kris, M. G.; Maslak, P. G.; Scheinberg, D. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Molecular characteristics predict clinical outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene
    Journal Article

    Rizvi, N. A.; Rusch, V.; Pao, W.; Chaft, J. E.; Ladanyi, M.; Miller, V. A.; Krug, L. M.; Azzoli, C. G.; Bains, M.; Downey, R.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans
    Journal Article

    Liu, F.; Zhao, B.; Krug, L. M.; Ishill, N. M.; Lim, R. C.; Guo, P.; Gorski, M.; Flores, R.; Moskowitz, C. S.; Rusch, V. W.; more...
    Journal of Thoracic Oncology (2010)

    Fulltext@MSK | Save